Survival and treatments are improving for this type of blood cancer.
You don’t expect to break a rib while doing … Article
Author Archives | admin
About admin
Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects
March 5, 2017
Abstract
Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been implicated in polyubiquitin-mediated IL-1R/TLR signaling through activation of IκB kinase
James R. Berenson, MD
- President & CEO, Institute for Myeloma & Bone Cancer Research (IMBCR)
- President & Medical Director. Berenson Cancer Center (Berensoncancercenter)
- Founder & President, ONCOtherapeutics
- Founder & Principal, ONCOtracker
-
Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study
-
IMBCR & Emory University’s Big Discovery!!!
-
James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
- What Is Multiple Myeloma?
-
Video Updates
- Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
- Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
- Understanding Myeloma News About Secondary Cancers and Clotting
-
Dedication of “Determination”
January 10, 2019
0 Comments